The administration of antibodies against IL-6 (BD+anti-IL-6+LT) raised parameters of damage (levels of transaminases, damage scores, ALP, total bilirubin, and also endothelial cell damage determined by vWF and HA levels) and inflammation (degree of neutrophil accumulation as measured by MPO, edema formation, and oxidative stress assessed using MDA) in non-steatotic grafts from DBDs, with respect to the results of the BD+LT group (Figures 2, 3). This evidence concerns the gene IL6 and Behcet disease.